Sanofi agrees manufacturing alliance with Isarna Therapeutics

Sanofi has announced a new strategic manufacturing agreement with Isarna Therapeutics, a developer of innovative cancer therapies.

The deal will see Sanofi manufacture clinical and commercial-grade antisense oligonucleotide (ASO) compounds on Isarna's behalf, allowing the firm to rapidly advance these new therapies to the clinical trial stage.

As part of the arrangement, Sanofi's industrial affairs division will act as Isarna's contract manufacturing organisation, scaling up and validating the production of ASOs and supplying future commercial batches.

This will allow Isarna to benefit from Sanofi's expertise in this field and the capabilities of its fully accredited in Frankfurt, Germany.

Dr Philippe Calais, chief executive officer of Isarna Therapeutics, said: "At Isarna, we are convinced that the best possible manufacturing is critical as we seek to maintain an accelerated timeline for product development."

This comes after Sanofi agreed to collaborate with Fraunhofer-Gesellschaft earlier this month to create a new centre for the creation of therapies to treat infectious diseases.